Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-hodgkin's lymphoma

British Journal of Haematology

Volumn 117, Issue 4, 2002, Pages 828-834

  Friedberg, Jonathan W ^a,b,c,d   Neuberg, Donna ^a   Gribben, John G ^a,b,c   Fisher, David C ^a,b,c   Canning, Christine ^a   Koval, Margaret ^a   Poor, Christine M ^a   Green, Luke M ^a   Daley, John ^a   Soiffer, Robert ^a,b,c   Ritz, Jerome ^a,b,c   Freedman, Arnold S ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

ADCC; Cytokines; Follicular non Hodgkin's lymphoma; IL 2; Rituxan

Indexed keywords

CHLORAMBUCIL; DIPHENHYDRAMINE; INTERLEUKIN 2; PARACETAMOL; RECOMBINANT INTERLEUKIN 2; RITUXIMAB;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EDEMA; EOSINOPHIL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPONATREMIA; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTE; MALE; MEDICAL ASSESSMENT; MIGRAINE; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; RELAPSE; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; CD8-POSITIVE T-LYMPHOCYTES; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; INTERLEUKIN-2; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECURRENCE; T-LYMPHOCYTES;

EID: 0036277742     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03535.x     Document Type: Article

References (46)

1. Phase II trial of outpatient interleukin 2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors
2. Phase I study of Inter-leukin-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma
3. Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin 2 and mitomycin C
4. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2
5. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2
6. Extended continuous infusion low-dose recombinant interleukin 2 in advanced cancer: Prolonged immunomodulation without significant toxicity
7. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
8. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
9. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
10. Clearing of cells bearing the bcl-2 [t(14:18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
11. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
12. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin 2 and interferon-alpha 2A immuno-therapy
13. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
14. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
15. Interleukin 2 signaling involves the phosphorylation of Stat proteins
16. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: Contribution of CD40 signaling in promoting survival
17. Interleukin 2 treatment in lymphoma: A phase II multicenter study
18. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
19. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
20. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
21. Anti-cd16/cd30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines
22. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
23. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation
24. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
25. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
26. Monoclonal antibody-based therapies for hematologic malignancies
27. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
28. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma
29. Effect of rituximab on apoptosis, necrosis and calcium signal transduction of CD20-expressing cell lines
30. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
31. Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin 2 (rhIL-2) therapy
32. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high-dose interleukin 2 alone
33. Monoclonal antibody therapy of murine lymphoma: Enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells
34. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
35. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells
36. Interleukin 2: Inception, impact, and implications
37. Effect of low-dose interleukin 2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation
38. Cytokines enhance rituximab-binding to tumor cells
39. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin 2 in combination with the B-cell-specific monoclonal antibody CLB-CD19
40. Immunotherapy for non-Hodgkin's lymphoma
41. Effector cell-mediated mechanisms play the dominant role in the cytotoxicity of rituximab on human peripheral blood B cells from normal donors and patients with chronic lymphocytic leukemia
42. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model
43. The use of interleukin 2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma
44. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
45. Constant-infusion recombinant interleukin 2 in adoptive immunotherapy of advanced cancer
46. IL-2 mediated NK cell expansion correlates with clinical response to rituximab: Results of two phase I trials of the combination of IL-2 and rituximab